Along with GBM cells, the results from patient-derived glioblastoma cells revealed that BY4003 and BY4008 significantly inhibited the growth and proliferation of patient-derived glioblastoma cells, with very lower concentrations than Tofacitinib indicated that BY4003 and BY4008 are the most potent, therapeutically sensitive and effective JAK3/STAT3 inhibitor having therapeutic potential to treat glioblastoma. Here, JAK3 is linked to glioblastoma.